Lexicon brings ACC data showing heart benefits across BMI groups New ACC posters include Phase 3 SCORED and SOTA-P-CARDIA analyses, showing HFpEF quality-of-life gains and reduced heart events regardless of BMI.

#LXRX Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

www.stocktitan.net/news/LXRX/lexicon-announ...

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1 study of LX9851, an oral non-incretin candidate for obesity.Lexicon earned a second $10 million milestone in 2026, may earn a third this year, and is eligible for up to $1 billion in total payments plus tiered royalties. The 96-subject trial is expected to complete in Q1 2027.

#LXRX Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than

#LXRX Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain Lexicon Pharmaceuticals (Nasdaq: LXRX) announced on January 21, 2026 that it completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for pilavapadin in diabetic peripheral neuropathic pain (DPNP).The FDA raised no objections to advancing pilavapadin into Phase 3, which the company plans as two placebo-controlled, 12-week, two-arm registrational studies evaluating a 10 mg daily dose versus placebo. The Phase 3 primary endpoint will be change in average daily pain score (ADPS) from baseline to Week 12. The FDA did not require unexpected preclinical or clinical studies that would likely delay Phase 3 or a potential regulatory submission.

#LXRX Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

www.stocktitan.net/news/LXRX/lexicon-pharma...

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.

#LXRX #VTRS Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

www.stocktitan.net/news/LXRX/viatris-expand...

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference Lexicon Pharmaceuticals (Nasdaq: LXRX) provided a business and pipeline update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and will present on January 15 at 12:00 p.m. PT (3:00 p.m. ET).Key program timelines: the pivotal SONATA-HCM Phase 3 study of sotagliflozin targets enrollment completion in mid-2026 with topline results expected in Q1 2027. ZYNQUISTA® (sotagliflozin) for type 1 diabetes remains on track for an NDA resubmission and potential approval in 2026 contingent on STENO1 patient exposure and safety data. Pilavapadin advanced via an End-of-Phase 2 meeting and partnership discussions continue.Commercial and finance: Lexicon triggered a $10 million milestone from Novo Nordisk for LX9851, has received $45 million to date with up to $950 million in remaining milestones plus tiered royalties, and ended 2025 with $125.2 million in cash, investments and restricted cash, which the company says supports operations into 2027

#LXRX Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/LXRX/lexicon-pharma...

Why a drugmaker is urging faster access to non-opioid pain relief A new Lexicon white paper urges action on chronic pain, affecting 1 in 4 adults and costing the U.S. $720B a year, to expand non-opioid treatments.

#LXRX Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” 

www.stocktitan.net/news/LXRX/lexicon-pharma...

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum Lexicon Pharmaceuticals (Nasdaq: LXRX) will present clinical data on sotagliflozin's effect on adipose tissue distribution in non-diabetic patients with HFpEF at CVCT 2025.The data derive from SOTA-P-CARDIA, a prospective, randomized, double-blind, placebo-controlled trial conducted by Mount Sinai Medical Center. The presentation is scheduled for Monday, December 8, 2025 at 10:30 a.m. ET and will be delivered by Juan Jose Badimon, Ph.D., at the 22nd Global Cardio Vascular Clinical Trialists Forum (December 8-10, 2025) at the Mayflower Hotel, Washington, D.C.Lexicon highlighted this dataset alongside recent cardiac remodeling and MACE data as additional evidence of sotagliflozin's differentiated effects versus SGLT2 inhibitors.

#LXRX Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

www.stocktitan.net/news/LXRX/clinical-data-...

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q3 2025 results and R&D updates on Nov 6, 2025. Key financials: Q3 revenue $14.2M (vs $1.8M YoY) driven by a $45M upfront from Novo Nordisk and $1.0M INPEFA sales; net loss $12.8M or $0.04/share (vs $64.8M). Cash and investments were $145.0M at Sept 30, 2025. Pipeline highlights: pilavapadin (LX9211) Phase 2b data support 10 mg dose and an FDA end-of-Phase 2 meeting in Q4 2025; LX9851 IND-enabling studies completed and licensed to Novo Nordisk (upfront $45M; up to $1B total; potential near-term $30M milestone); SONATA-HCM Phase 3 site initiation complete with 130 sites and enrollment target 500; Zynquista resubmission data submitted to FDA.

#LXRX Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company

#LXRX Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)

#LXRX Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting now expected during the

#LXRX Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

www.stocktitan.net/news/LXRX/lexicon-pharma...

#LXRX & #SGMO joining the pumpers today. Potential for multi day moves.

30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek Study highlights physical and psychological impact of diabetic peripheral neuropathic pain (DPNP) affecting 25-30% of diabetic neuropathy patients. Research focuses on treatment challenges.

#LXRX Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both

#LXRX Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/LXRX/lexicon-pharma...

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology Lexicon Pharmaceuticals (NASDAQ: LXRX) presented the design of its SONATA-HCM Phase 3 clinical trial at Heart Failure 2025, evaluating sotagliflozin for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). The study is actively enrolling 500 patients across 20 countries, with all sites expected to be operational by September 2025.The trial aims to assess sotagliflozin's efficacy on symptoms, function, and patient-reported outcomes in HCM patients. The primary endpoint measures symptom improvement using the Kansas City Cardiomyopathy Questionnaire at week 26. Recent evidence published in The Lancet (February 2025) suggests sotagliflozin's dual SGLT1 and SGLT2 inhibition reduces major adverse cardiovascular events.If successful, the study could support a supplemental new drug application (sNDA) for sotagliflozin in both HCM types, addressing a significant unmet need, particularly for non-obstructive HCM where no approved therapies exist.

#LXRX SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

www.stocktitan.net/news/LXRX/sonata-hcm-stu...

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates Lexicon Pharmaceuticals (LXRX) reported Q1 2025 financial results and business updates. The company secured an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion in payments. Their Phase 2b PROGRESS study confirmed 10 mg pilavapadin as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain. Q1 financial results showed revenues of $1.3 million, R&D expenses of $15.3 million, and reduced SG&A expenses to $11.6 million. Net loss improved to $25.3 million ($0.07 per share) from $48.4 million in Q1 2024. The company ended Q1 with $194.8 million in cash and investments. Lexicon is advancing multiple pipeline programs, including sotagliflozin for hypertrophic cardiomyopathy in the SONATA-HCM Phase 3 study.

#LXRX Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/LXRX/lexicon-pharma...

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #KPTI 1.2x
2. #LX 0.1x
3. #LXRX 1.5x
4. #ONDS 2.8x
5. #RDDT 0.2x

#OptionFlow #OptionsTrading #Trading

News; ( NASDAQ: #LXRX ) Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #DT 3.4x
2. #UMC 3.3x
3. #RBRK 2.9x
4. #CCI 2.5x
5. #LXRX 2.2x

#OptionFlow #OptionsTrading #Trading

News; ( NASDAQ: #LXRX ) Lexicon Lands up to $1B Novo Nordisk Deal for LX9851 Obesity Game-Changer

NEWS: ( NASDAQ: #LXRX ) Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal First-in-class oral obesity drug LX9851 shows promising synergy with semaglutide. $75M upfront payment plus $1B in potential milestones. See full deal terms.

#LXRX Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

www.stocktitan.net/news/LXRX/lexicon-pharma...

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Lexicon Pharmaceuticals (LXRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its R&D pipeline. The company's Q4 2024 revenues increased to $26.6 million from $0.7 million in Q4 2023, including a $25.0 million upfront payment from the Viatris INPEFA licensing agreement.Key developments include positive topline results from the PROGRESS Phase 2b study of pilavapadin (LX9211) for diabetic peripheral neuropathic pain, with the 10 mg dose advancing to Phase 3 development in 2025. The company is also progressing with LX9851 for obesity and continuing enrollment in the SONATA HCM Phase 3 trial for sotagliflozin.Financial highlights show Q4 2024 net loss of $33.8 million ($0.09 per share), compared to $49.8 million ($0.20 per share) in Q4 2023. R&D expenses increased to $26.7 million, while SG&A expenses slightly decreased to $32.3 million. The company ended 2024 with $238.0 million in cash and short-term investments.

#LXRX Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/LXRX/lexicon-pharma...

NEWS: ( NASDAQ: #LXRX ) Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Can Lexicon's Non-Opioid Pain Drug Break 20-Year Innovation Drought? Phase 2b Results Reveal Path Forward Despite missing statistical significance, Lexicon's 10mg pilavapadin demonstrated meaningful pain reduction with improved tolerability, setting stage for Phase 3 trials.

#LXRX Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

www.stocktitan.net/news/LXRX/lexicon-pharma...

Can Lexicon's Non-Opioid Drug Transform Diabetic Pain Treatment? Phase 2b Results Coming Lexicon schedules March 2025 presentation of topline data for pilavapadin, a first-in-class non-opioid treatment targeting diabetic neuropathic pain via AAK1 inhibition.

#LXRX Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

www.stocktitan.net/news/LXRX/lexicon-pharma...

Revolutionary Diabetes Drug Cuts Heart Attack Risk by 32% - Landmark Study Results Lancet study reveals sotagliflozin significantly reduces cardiovascular events in diabetes patients, outperforming other treatments in stroke prevention.

#LXRX Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

www.stocktitan.net/news/LXRX/published-data...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MSTR, #LXRX, #KC, #LMND, #LCID

#OptionFlow #OptionsTrading #Trading